Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May;94(5):725-8.
doi: 10.3324/haema-tol.2008.000893.

Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration

Ersi Voskaridou  1 , Dimitrios Christoulas, Charoula Xirakia, Konstantinos Varvagiannis, Georgios Boutsikas, Antonios Bilalis, Efstathios Kastritis, Athanasios Papatheodorou, Evangelos Terpos
Affiliations

Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration

Ersi Voskaridou et al. Haematologica. 2009 May.

Erratum in

  • Haematologica. 2009 Aug;94(8):1182

Abstract

Dickkopf-1 is an inhibitor of Wnt signaling, which is crucial for osteoblast differentiation. We evaluated serum levels of Dickkopf-1 in 66 patients with thalassemia-induced osteoporosis who received therapy with zoledronic acid in a placebo-controlled, randomized trial. At baseline, thalassemia patients had increased serum levels of Dickkopf-1 that correlated with reduced bone mineral density of the lumbar spine and the distal radius. High Dickkopf-1 also correlated with increased bone resorption and reduced bone formation markers. Zoledronic acid produced a reduction in serum Dickkopf-1, which was associated with bone mineral density increase after 12 months of therapy. On the contrary, placebo group showed a borderline increase of Dickkopf-1, which was higher in patients who showed deterioration in pain scores. These results suggest that Dickkopf-1 is implicated in the pathogenesis of osteoporosis in thalassemia and reveal Dickkopf-1 as a possible target for the development of novel agents for the management of thalassemia-induced osteoporosis.

Trial registration: ClinicalTrials.gov NCT00346242.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patients with thalassemia and osteoporosis have increased levels of serum Dkk1 compared with normal controls (A). Increased Dkk1 levels correlated with reduced BMD of the lumbar spine (B) and the wrist (C) but also with reduced bALP (bone formation marker) (D).
Figure 2.
Figure 2.
Zoledronic acid administration produced a reduction in Dkk1 serum levels but in placebo group a borderline increase of Dkk1 was observed.
See this image and copyright information in PMC

References

    1. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with β thalassaemia. Br J Haematol. 2004;127:127–39. - PubMed
    1. Voskaridou E, Kyrtsonis MC, Terpos E, Voskaridou E, Kyrtsonis MC, Terpos E, et al. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol. 2001;112:36–41. - PubMed
    1. Voskaridou E, Terpos E, Spina G, Skordili M, Palermos J, Rahemtulla A, et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol. 2003;123:730–7. - PubMed
    1. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, et al. Zoledronic acid for the treatment of osteoporosis in patients with β-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica. 2006;91:1193–202. - PubMed
    1. Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E. Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica. 2008;93:1588–90. - PubMed

MeSH terms

Associated data